|
1
|
Loeper S, Romeike BF, Heckmann N, Jung V,
Henn W, Feiden W, Zang KD and Urbschat S: Frequent mitotic errors
in tumor cells of genetically microheterogeneous glioblastomas.
Cytogenet Cell Genet. 94:1–8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu M, Chen Q, Li D, Li X, Li X, Huang C,
Tang Y, Zhou Y, Wang D, Tang K, et al: LRRC4 inhibits human
glioblastoma cells proliferation, invasion, and proMMP-2 activation
by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling
pathways. J Cell Biochem. 103:245–255. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maher EA, Furnari FB, Bachoo RM, Rowitch
DH, Louis DM, Cavenee WK and DePinho RA: Malignant glioma: genetics
and biology of a grave matter. Gene Dev. 15:1311–1333. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJB, et al: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. New Engl J Med.
352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hockel M, Schlenger K, Aral B, et al:
Association between tumor hypoxia and malignant progression in
advanced cancer of the uterine cervix. Cancer Res. 56:4509–4515.
1996.PubMed/NCBI
|
|
7
|
Woodhouse EC, Chuaqui RF and Liotta LA:
General mechanisms of metastasis. Cancer. 80:1529–1537. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Van Noorden CJ: Proteases and protease
inhibitors in cancer. Acta Histochem. 100:344–354. 1998.PubMed/NCBI
|
|
9
|
Sternlicht MD and Werb Z: How matrix
metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol.
17:463–516. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Choe G, Park JK, Jouben-Steele L, Kremen
TJ, Liau LM, et al: Active matrix metalloproteinase 9 expression is
associated with primary glioblastoma subtype. Clin Cancer Res.
8:2894–2901. 2002.PubMed/NCBI
|
|
11
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Forsyth PA, Wong H, Laing TD, Rewcastle
NB, Morris DG, et al: Gelatinase-A (MMP-2), gelatinase-B (MMP-9)
and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved
in different aspects of the pathophysiology of malignant gliomas.
Br J Cancer. 79:1828–1835. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vogt A, Sun J, Qian Y, Hamilton AD and
Sebti SM: The geranylgeranyltransferase-I inhibitor GGTI-298
arrests human tumor cells in G0/G1 and induces p21 (WAF1/CIP1/SDI1)
in a p53-independent manner. J Biol Chem. 272:27224–27229. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laufs U and Liao JK: Post-transcriptional
regulation of endothelial nitric oxide synthase mRNA stability by
Rho GTPase. J Biol Chem. 273:24266–24271. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Noguchi Y, Nakamura S, Yasuda T, Kitagawa
M, Kohn LD, Saito Y and Hirai A: Newly synthesized RhoA, not Ras,
is isoprenylated and translocated to membranes coincident with
progression of the G1 to S phase of growth-stimulated rat FRTL-5
cells. J Biol Chem. 273:3649–3653. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wong WW, Dimitroulakos J, Minden MD and
Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: the
statin family of drugs as triggers of tumor-specific apoptosis.
Leukemia. 16:508–519. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Graaf MR, Richel DJ, van Noorden CJ and
Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors
on the development and progression of cancer. Cancer Treat Rev.
30:609–641. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Denoyelle C, Vasse M, Korner M, Mishal Z,
Ganne F, Vannier JP, Soria J and Soria C: Cerivastatin, an
inhibitor of HMG-CoA reductase, inhibits the signaling pathways
involved in the invasiveness and metastatic properties of highly
invasive breast cancer cell lines: an in vitro study.
Carcinogenesis. 22:1139–1148. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sawada K, Morishige K, Tahara M, Kawagishi
R, Ikebuchi Y, Tasaka K and Murata YL: Alendronate inhibits
lysophosphatidic acid-induced migration of human ovarian cancer
cells by attenuating the activation of rho. Cancer Res.
62:6015–6020. 2002.
|
|
20
|
Kusama T, Mukai M, Tatsuta M, Nakamura H
and Inoue M: Inhibition of transendothelial migration and invasion
of human breast cancer cells by preventing geranylgeranylation of
Rho. Int J Oncol. 29:217–223. 2006.PubMed/NCBI
|
|
21
|
Sullivan R and Graham CH: Hypoxia-driven
selection of the metastatic phenotype. Cancer Metastasis Rev.
26:319–331. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fujiwara S, Nakagawa K, Harada H, Nagato
S, Furukawa K, Teraoka M, Seno T, Oka K, Iwata S and Ohnishi T:
Silencing hypoxia-inducible factor-1alpha inhibits cell migration
and invasion under hypoxic environment in malignant gliomas. Int J
Oncol. 30:793–802. 2007.PubMed/NCBI
|
|
23
|
Bruland OS, Hoifodt H, Saeter G, Smeland S
and Fodstad O: Hematogenous micrometastases in osteosarcoma
patients. Clin Cancer Res. 11:4666–4673. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Coussens LM, Fingleton B and Matrisian LM:
Matrix metalloproteinase inhibitors and cancer: trials and
tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Forsyth PA, Wong H, Laing TD, Rewcastle
NB, Morris DG, et al: Gelatinase-A (MMP-2), gelatinase-B (MMP-9)
and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved
in different aspects of the pathophysiology of malignant gliomas.
Br J Cancer. 79:1828–1835. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS,
Lee SH, Park IC, Rhee CH and Hong SI: Ionizing radiation enhances
matrix metalloproteinase-2 secretion and invasion of glioma cells
through Src/epidermal growth factor receptor-mediated p38/Akt and
phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res.
66:8511–8519. 2006. View Article : Google Scholar
|
|
28
|
Arias J, Alberts AS, Brindle P, Claret FX,
Smeal T, Karin M, Feramisco J and Montminy M: Activation of cAMP
and mitogen responsive genes relies on a common nuclear factor.
Nature. 370:226–229. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bannister AJ, Oehler T, Wilhelm D, Angel P
and Kouzarides T: Stimulation of c-Jun activity by CBP: c-Jun
residues Ser63/73 are required for CBP induced stimulation in vivo
and CBP binding in vitro. Oncogene. 11:2509–2514. 1995.PubMed/NCBI
|
|
30
|
Fromigué O, Hamidouche Z and Marie PJ:
Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces
osteosarcoma cell invasion. J Biol Chem. 283:30549–30556.
2008.PubMed/NCBI
|
